Breaking News

Goodwin Biotech to Manufacture Aspyrian ADC Candidate

Will complete process development, scale-up, and cGMP manufacture for trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Goodwin Biotechnology has partnered with Aspyrian Therapeutics to complete process development, scale-up, and cGMP manufacture of their novel Antibody Drug Conjugate (ADC). Aspyrian recently received FDA acceptance of an IND application for RM-1929, a precision targeted therapy for cancer, and will be initiating clinical trials in patients with recurrent head and neck cancer.   “The team at Goodwin Biotechnology takes great pride in partnering with our clients and advancing their biophar...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters